Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tomoyuki Matsumoto"'
Autor:
Tomoaki Fukui, Takahiro Niikura, Takahiro Oda, Yohei Kumabe, Hiroyuki Ohashi, Masahiro Sasaki, Tatsushi Igarashi, Makoto Kunisada, Nozomi Yamano, Keisuke Oe, Tomoyuki Matsumoto, Takehiko Matsushita, Shinya Hayashi, Chikako Nishigori, Ryosuke Kuroda
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0235948 (2020)
INTRODUCTION:Surgical site infection is one of the most severe complications of surgical treatments. However, the optimal procedure to prevent such infections remains uninvestigated. Ultraviolet radiation C (UVC) with a short wavelength has a high ba
Externí odkaz:
https://doaj.org/article/d65de311f01d4bf89efb513626ffa8db
Autor:
Hiroto Iwasaki, Atsuhiko Kawamoto, Marc Tjwa, Miki Horii, Saeko Hayashi, Akira Oyamada, Tomoyuki Matsumoto, Shigefumi Suehiro, Peter Carmeliet, Takayuki Asahara
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24872 (2011)
Despite preclinical success in regenerating and revascularizing the infarcted heart using angiogenic growth factors or bone marrow (BM) cells, recent clinical trials have revealed less benefit from these therapies than expected.We explored the therap
Externí odkaz:
https://doaj.org/article/004d51c656d649998e8bcb5094d6a224
Autor:
Tatsushi Igarashi, Takahiro Niikura, Takahiro Oda, Shinya Hayashi, Makoto Kunisada, Ryosuke Kuroda, Tomoyuki Matsumoto, Takehiko Matsushita, Masahiro Sasaki, Tomoaki Fukui, Keisuke Oe, Nozomi Yamano, Hiroyuki Ohashi, Yohei Kumabe, Chikako Nishigori
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 8, p e0235948 (2020)
PLoS ONE, Vol 15, Iss 8, p e0235948 (2020)
Introduction Surgical site infection is one of the most severe complications of surgical treatments. However, the optimal procedure to prevent such infections remains uninvestigated. Ultraviolet radiation C (UVC) with a short wavelength has a high ba
Autor:
Peter Carmeliet, Tomoyuki Matsumoto, Shigefumi Suehiro, Saeko Hayashi, Hiroto Iwasaki, Akira Oyamada, Takayuki Asahara, Miki Horii, Marc Tjwa, Atsuhiko Kawamoto
Publikováno v:
PLoS ONE
PLoS ONE, Vol 6, Iss 9, p e24872 (2011)
PLoS ONE, Vol 6, Iss 9, p e24872 (2011)
Rationale Despite preclinical success in regenerating and revascularizing the infarcted heart using angiogenic growth factors or bone marrow (BM) cells, recent clinical trials have revealed less benefit from these therapies than expected. Objective W